Cingulate Inc. (CINGW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Peers in industry
Cingulate Inc. has no peer companies in this window.
Recent press releases
Cingulate Inc. has not issued a press release in this window.
SEC filings
All filings →Cingulate Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Cingulate Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Cingulate Inc.
All people →No officers or directors have been indexed for Cingulate Inc..